MétaCan
Menu
Back to cohort
Record W3125193724

COVID19 on U.S. and canadian neurologists' therapeutic approach to multiple sclerosis: A survey of knowledge, attitudes, and practices

2020· article· en· W3125193724 on OpenAlexaboutno aff
Andre C. Vogel, Shadi Rezai, Nicholas Alakel, Brittany Gazdag, A. Kumar, Farrukh Mateen

Bibliographic record

VenueMultiple Sclerosis Journal · 2020
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineMultiple sclerosisPandemicCoronavirus disease 2019 (COVID-19)Family medicineInclusion (mineral)PsychiatryPsychologyDiseaseInternal medicine
DOInot available

Abstract

fetched live from OpenAlex

Background: There have been >1 8 million cases of Sars-CoV-2 (Covid19) in the USA and >100,000 deaths reported as of June 2020 Immunosuppression is reported as a risk factor for developing Covid19 Amidst this pandemic and declared national emergency in the USA, with a parallel response in Canada, neuroimmunologists are making important decisions and adjudicating complex situations of risk for their patients living with MS No synthesized study of North American neuroimmunologists' perceptions has been conducted Objectives: To report the experiences, opinions, and decisionmaking of U S and Canadian neuroimmunologists as they relate to the treatment of patients with multiple sclerosis (MS) during the Covid19 pandemic of 2020 Methods: A new survey instrument was designed and distributed electronically Invitations were sent via a known panel of MS neurologists and to publicly available e-mail addresses of MS-focused U S and Canadian neurologists, April 14-May 3, 2020 Inclusion criteria included treating at least 10 MS patients in the prior 6 months Results: 243 respondents (average 197 MS patients seen in the prior 6 months (i e pre-Covid19);average practice duration 16 years;92% USA, 8% Canada;5% rural, 17% small city, 38% large city, 40% highly urbanized) met our inclusion criteria MS patient volume dropped by 79% on average (from 53 to 11 patients per month) during the time of Covid19 23% of neurologists were aware of patients self-discontinuing a DMT due to fear of Covid19 with 43% estimated to be doing so against medical advice 65% of respondents reported deferring >=1 doses of a disease modifying therapy (DMT) (49%), changing the dosing interval (34%), changing to home infusions (20%), switching a DMT (9%), and discontinuing DMTs altogether (8%) due to Covid19 Changes in DMT administration were most common among the higher-efficacy therapies alemtuzumab, cladribine, ocrelizumab, rituximab, and natalizumab;however, 35% of neurologists reported making no changes to DMT prescribing 98% of respondents expressed worry about their patients contracting Covid19 and 78% expressed the same degree of worry about themselves >50% reported believing that high-efficacy DMTs prolong viral shedding of SARS-CoV-2 and that B-cell therapies might prevent protective vaccine effects Accelerated pace of telemedicine was identified as a major shift in practice Conclusions: Reported prescribing changes and practice disruptions due to Covid19 may be temporary but are likely to have a long-lasting influence on MS patients and their care

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.012
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.041
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.012
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.315
GPT teacher head0.359
Teacher spread0.043 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueMultiple Sclerosis JournalSame topicMultiple Sclerosis Research StudiesFrench-language works237,207